Michael Grey Joins Mirati Therapeutics (MRTX) Board Of Directors

Michael Grey Joins Mirati Therapeutics  (MRTX) Board Of Directors

SAN DIEGO, Nov. 6, 2014 /PRNewswire/ --- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that biotechnology industry veteran Michael Grey has joined its board of directors.

"Mike's extensive experience in the pharmaceutical and biotechnology industries, including senior leadership and board positions in several successful companies, will complement and strengthen our Board," said Charles M. Baum, M.D. Ph.D., president and CEO of Mirati. "His expertise in developing strategy, identifying growth opportunities and building organizations is invaluable as we advance our targeted oncology medicines to the market."

Mr. Grey currently serves on the board of directors of BioMarin Pharmaceutical Inc., Horizon Pharma plc, and Selventa, Inc. He is also the chairman and chief executive officer at Reneo Pharmaceuticals, Inc., and a venture partner at Pappas Ventures.

Previously, Mr. Grey was president and chief executive officer at Lumena Pharmaceuticals, Inc. until its acquisition by Shire plc. He has held senior positions at a number of companies, including president and chief executive officer of Auspex Pharmaceuticals, Inc., president and chief executive officer of SGX Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2008, president and chief executive officer of Trega Biosciences, Inc., which was acquired by Lion Bioscience in 2001, and president of BioChem Therapeutic Inc. Before that, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings plc over a 20 year tenure, culminating in his position as vice president, corporate development and director of international licensing. He received a B.Sc. in chemistry from the University of Nottingham in the United Kingdom.

About Mirati Therapeutics
Mirati Therapeutics is a targeted oncology company developing oncology therapeutics for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development drug candidates targeting genetic and epigenetic drivers of cancer, creative and agile clinical development that selects for patients whose tumors are dependent on those driver alterations, and a highly accomplished precision medicine leadership team. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths. Mirati is currently advancing three drug candidates through clinical development for multiple oncology indications. More information is available at www.mirati.com.

Company Contact:

Investor Relations and Media Relations:

Mirati Therapeutics Inc.

Jason Spark

Mark J. Gergen

Canale Communications

Executive Vice President & COO



[email protected]

SOURCE Mirati Therapeutics, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.